Previous Article | Next Article 
Journal of Virology, December 2001, p. 11992-11998, Vol. 75, No. 24
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.24.11992-11998.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Hepatitis C Virus Core and Envelope Proteins Do Not Suppress
the Host's Ability To Clear a Hepatic Viral Infection
Jiaren
Sun,*
Francis
Bodola,
Xuegong
Fan,
Habib
Irshad,
Lynn
Soong,
Stanley
M.
Lemon, and
Teh-Sheng
Chan
Department of Microbiology and Immunology,
University of Texas Medical Branch at Galveston, Galveston, Texas
77555-1070
Received 5 June 2001/Accepted 14 September 2001
 |
ABSTRACT |
Several hepatitis C virus (HCV) proteins have been shown in vitro
to interact with host cellular components that are involved in immune
regulation. However, there is a paucity of data supporting the
relevance of these observations to the in vivo situation. To test the
hypothesis that such an interaction suppresses immune responses, we
studied a line of transgenic C57BL/6 mice that express the HCV core and
envelope proteins in the liver. The potential effects of these proteins
on the hepatic immune response were evaluated by challenging these mice
with a hepatotropic adenovirus. Both transgenic and nontransgenic mice
developed similar courses of infection and cleared the virus from the
liver by 28 days postinfection. Both groups of mice mounted similar
immunoglobulin G (IgG), IgG2a, interleukin-2, and tumor necrosis factor
alpha responses against the virus. Additionally, BALB/c mice were able
to clear infection with recombinant adenovirus that does or does not
express the HCV core and envelope 1 proteins in the same manner. These
data suggest that HCV core and envelope proteins do not inhibit the hepatic antiviral mechanisms in these murine experimental systems and
thus favor a model in which HCV circumvents host responses through a
mechanism that does not involve general suppression of intrahepatic
immune responses.
 |
INTRODUCTION |
Hepatitis C virus (HCV), a
major cause of chronic liver disease worldwide, currently infects about
1.8% of the U.S. population (1). Most HCV-infected
patients become chronically infected, and a substantial proportion of
such patients develop clinical manifestations of liver disease.
Although the natural history of the chronic infection is not well
understood, the high frequency with which infection progresses to
chronicity suggests that HCV has evolved specific mechanisms to
circumvent the host's immune responses.
A number of distinct models have been proposed to explain the
phenomenon of persistent HCV infection. Several studies have described
the emergence of viral variants that could escape from the immune
system. During the course of a chronic infection, antibodies (Abs)
recognizing hypervariable region 1 of the viral E2 envelope protein
undergo changes in their epitope specificities. In addition, cytotoxic
T lymphocytes (CTL) from a chronically infected chimpanzee failed to
recognize the HCV quasispecies present at 4 months postinfection (3, 25). Collectively, these studies suggest that, despite active immune responses, a viral population may emerge with the selection of variants that possess an enhanced ability to persist in
the host.
On the other hand, the establishment of a persistent HCV infection may
not always be due to genetic variation of the virus (15).
It has been suggested that HCV, like adenovirus, herpes simplex virus,
and many other viruses, may encode one or more proteins that act to
inhibit viral clearance by the host. Indeed, two viral proteins, NS5A
and the envelope glycoprotein E2, have been shown to repress the
host's double-stranded-RNA-inducible protein kinase R (PKR), resulting
in a state of selective interferon (IFN) resistance (7,
21). When expressed in mammalian cells, NS5A confers IFN
resistance on vesicular stomatitis virus, which normally is sensitive
to the antiviral actions of IFN (6). In addition, the HCV
core protein has been shown to bind to the cytoplasmic domains of tumor
necrosis factor (TNF) receptor 1, lymphotoxin
receptor, and gC1q
receptor (4, 13, 17, 28), resulting in interference with
Fas/TNF-
-induced apoptosis and T-cell proliferation in vitro
(8, 16).
Given the roles of these cellular proteins in the normal development of
peripheral lymphoid organs, transduction of apoptotic signals, and
initiation and resolution of inflammation (18, 24), these
data raise the possibility that the HCV structural proteins (core, E1,
and E2) have significant immunomodulatory functions. However, there is
a paucity of data either supporting or refuting the relevance of these
in vitro observations to the in vivo situation. To distinguish between
the relative contributions of evasive and suppressive factors in HCV
persistence in vivo, we took advantage of a recently developed HCV
transgenic (tg) mouse (14a) and examined the effects
of the HCV structural proteins on intrahepatic immune
responses during a viral infection. Our data suggest that the
HCV core and envelope proteins are not inherently immunosuppressive in murine experimental systems and thus favor a model
in which HCV circumvents immune responses through a mechanism that does
not require profound immune suppression.
 |
MATERIALS AND METHODS |
Mice.
Generation of HCV tg mice has been described in detail
elsewhere (14a). Briefly, cDNA corresponding to the
structural protein coding region (core, E1, and E2/p7) of the genotype
1b HCV-N strain of HCV was subcloned into plasmid pGEMAlbSVPA under the
control of the liver-specific murine albumin promoter-enhancer. The
insert was excised by digestion with XhoI and injected into
F1 hybrid zygotes (C3H/HeJ × C57BL/6J). The offspring were
screened for the presence of tg DNA by Southern blot analysis, and a tg
F0 founder (S-N/863) was mated with C57BL/6 mice
(H-2b; Jackson Laboratories, Bar Harbor,
Maine) to produce F1 and subsequent generations
of animals. BALB/c mice (H-2d) were
purchased from Jackson Laboratories. All mice were housed in a
specific-pathogen-free facility. The Institutional Animal Care and Use
Committee of the University of Texas Medical Branch approved the study.
Viral infection of the liver.
Tg and non-tg mice were
infected with a replication-impaired (with E1 deleted) adenovirus
(Ad
gal) that expresses bacterial
-galactosidase (
-Gal), as
previously reported by Herz and Gerard (9). Ten tg mice, 2 to 3 months of age, were each inoculated intravenously with 3 × 109 PFU of Ad
gal. Equal numbers of age-matched
non-tg littermates were infected as controls. In separate experiments,
20 2-month-old female BALB/c mice were similarly infected with 3 × 108 PFU of Ad
gal and a recombinant
adenovirus expressing the core and E1 segments of the HCV polyprotein
(AdCE1) (2). At 3 to 6, 14, and 28 days postinfection, two
to four mice in each group were sacrificed by CO2
asphyxiation. Liver tissues were snap frozen in liquid nitrogen for DNA
isolation or placed in OCT cryostat-embedding compound (Tissue-Tek,
Torrance, Calif.) for morphological analyses. Serum samples were stored
at
70°C for subsequent enzyme-linked immunosorbent assays (ELISAs)
and alanine aminotransferase (ALT) measurements.
Immunohistochemistry and Western blotting.
After being fixed
in acetone and blocked with normal goat serum and avidin-biotin
(Avidin/Biotin blocking kit; Vector Laboratories, Burlingame, Calif.),
cryosections were incubated at 4°C overnight with a rabbit
anti-peptide antibody specific for the E2 protein of HCV-N (1:500). The
sections were incubated with biotinylated goat anti-rabbit
immunoglobulin G (IgG) followed by avidin-conjugated peroxidase
(Vectastain Elite ABC kit) and developed in 3,3'-diaminobenzidine tetrahydrochloride. Detection of lymphocytes in tissue samples was
carried out as described previously (20). For
immunoblotting, 2 µg of protein extracted from the livers of mice
infected with AdCE1 and Ad
gal or from a stably transfected cell
line, Huh7/191-20, that expresses HCV core, E1, and E2 proteins were
electrophoresed in a sodium dodecyl sulfate-12% polyacrylamide gel
(unpublished data). The proteins were electrotransferred to a
polyvinylidene difluoride membrane (Bio-Rad, Hercules, Calif.) and
probed with a mixture of monoclonal Abs (MAbs) specific for HCV core
(Anogen, Mississauga, Canada),
-actin (Sigma, St. Louis, Mo.), and
adenovirus hexon protein (Chemicon, Temecula, Calif.), followed by a
horseradish peroxidase-conjugated anti-mouse IgG (Southern
Biotechnology Associates, Birmingham, Ala.) and enhanced
chemiluminescence detection reagents (Amersham Pharmacia Biotech,
Little Chalfont, England).
Detection of Ad
gal in liver cryosections.
Following a
brief fixation with 0.5% glutaraldehyde, frozen liver sections were
incubated with 0.2 mg of X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside)/ml at
37°C for 60 to 120 min. Infected cells expressing
-Gal activity were stained blue, whereas uninfected cells were counterstained red
(neutral red). Five images from two liver sections were randomly selected and captured with a Zeiss Axioskop microscope equipped with a
Sony DXC-970MD video camera (10× objectives). Infected and uninfected
regions were quantified using the MetaView Imaging System 4.0 software
(Universal Imaging System, West Chester, Pa.). Thresholds were selected
with colors representative of the desired color range of the infected
or uninfected cells. Infectivity of the hepatocytes was expressed as
the average ratio of infected to uninfected cells.
Determination of hepatic viral load.
The Ad
gal copy
numbers in the liver were assessed by real-time quantitative PCR. Total
DNA was extracted from 50 mg of liver tissue from each mouse by using a
QIAamp DNA Mini Kit (Qiagen Inc., Valencia, Calif.). Analysis was
carried out on a Roche LightCycler with its core reagent kit (DNA
Master SYBR Green 1). The PCR primers corresponding to the adenovirus
hexon gene were 5'-GAGCCAGCATTAAGTTTGATAGCA-3' and
5'-AGATAGTCGTTAAAGGACTGGTCGTT-3'. The extracted DNA samples were diluted 1:100 with Tris-EDTA buffer, and 5-µl aliquots were placed in glass capillary cuvettes (Roche) containing 15 µl of PCR
master mix. Reaction cycles included denaturation at 94°C for 30 s, annealing at 60°C for 5 s, and extension at 72°C for 10 s. The reaction produced a 126-bp product. The observed
threshold cycle for a no-template control was typically around 35 cycles. The standard curve of the threshold cycles versus the template abundance was linear over 5 orders of magnitude, with a regression correlation typically greater than 0.98. All data were combined from
two independent experiments.
Measurements of serum IgG and cytokines.
Serum samples were
analyzed for adenovirus-specific IgG by ELISA with a procedure modified
from a previous report by Chirmule et al. (5). Briefly,
96-well Immunolon-IV microtiter plates (Dynatech, Chantilly, Va.) were
coated with Ad
gal (108 particles/ml). Serum
dilutions (1:50) were added to duplicate wells, and the plates
were incubated at 4°C overnight. The plates were incubated with
biotinylated rabbit anti-mouse IgG or IgG2a, followed by
avidin-conjugated peroxidase (BD PharMingen). The enzyme activity was
determined calorimetrically using O-phenylenediamine dihydrochloride reagent (Sigma) and read at 492 nm. Interleukin-2 (IL-2) and TNF-
in the serum samples were measured with commercial ELISA kits (BD PharMingen) according to the manufacturer's
recommendations. The paired MAbs specific for IL-2 and TNF-
were
JES6-1A12/JES6-5H4 and G281-2626/MP6-XT3, respectively. Serum samples
(1:3) were incubated in the plates at 4°C overnight, followed by
incubation with a biotinylated anti-IL-2 or anti-TNF-
MAb.
Avidin-conjugated peroxidase was added to the plates, and the enzyme
activity was determined calorimetrically as described above.
TUNEL assay for detection of apoptosis in situ.
The terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling
(TUNEL) assay was carried out on deparaffinized, formalin-fixed liver
sections treated with proteinase K (20 mg/ml). After endogenous
peroxidase was blocked by immersing the sections in 3%
H2O2 for 30 min, slides
were incubated with a buffer solution containing terminal
deoxynucleotide transferase and digoxigenin-labeled deoxynucleotide
triphosphates (ApopTag Peroxidase; Intergen Company, Purchase, N.Y.) in
a humidified chamber at 37°C for 1 h. An
antidigoxigenin-peroxidase conjugate was added for 30 min, followed by
3,3'-diaminobenzidine tetrahydrochloride as a chromogen. The slides
were scored blindly with respect to the tg status of the animal. One
section from each mouse was examined in each of two independent assays.
The total number of apoptotic cells in 10 randomly selected microscopic fields (40×) was scored in each section.
Statistical analysis.
All statistical evaluations were
conducted using analysis of variance for two factors, independently and
interactively. Tabulations were facilitated by using Abstat 1.90 software (Anderson-Bell Corp., Arvada, Colo.).
 |
RESULTS |
Since the intrahepatic immune system has a number of unique
properties, including lymphocyte populations that are distinct from
those of the spleen and lymph nodes (19), it is important to examine the potential immunosuppressive effects of HCV proteins in
the context of the hepatic microenvironment. To assess the role of HCV
structural proteins expressed at levels similar to those encountered in
infected humans, we used a tg mouse line with liver-specific expression
of HCV core, E1, and E2/p7 proteins. Immunocompetent mice are capable
of eliminating recombinant adenovirus primarily through a cellular
immune response (27, 29). Thus, the prolonged presence of
adenovirus in these tg mice would support the view that the HCV
structural proteins suppress the immune system.
First, we evaluated the expression of the HCV transgene in the tg mice.
The E2 protein was expressed in tg liver tissue with a distribution
that was cytoplasmic and particularly prominent in the pericentral
regions (Fig. 1A). No E2
antigen was present in non-tg mice. RNA transcripts
of the transgene were detectable in the livers of tg mice by Northern
blot analysis (14a). Next, we infected these mice and
their non-tg littermates with a recombinant adenovirus (Ad
gal) that
expresses a reporter
-Gal. When 3 × 109
PFU of Ad
gal was injected through the tail vein, the hepatotropism of the virus was evidenced by
-Gal staining of the liver but not the
spleen, kidneys, or lungs (data not shown). Three groups of mice in
each of two experiments were sacrificed during the early (days 3 to 6),
intermediate (day 14), and late (day 28) stages of the infection. Both
tg and non-tg mice demonstrated a striking hepatic infection during the
early stage (Fig. 1B). The
-Gal activity was easily detectable in
infected hepatocytes, and the excellent contrast between
-Gal and
neutral red (counterstain) allowed accurate enumeration of infected
hepatocytes. The results from these experiments showed that tg and
non-tg mice followed similar courses of infection, with the
disappearance of most Ad
gal-infected hepatocytes by 28 days
postinfection (Fig. 1B and 2A). To
provide an independent measure of viral clearance, we also determined the viral load in the liver tissues by a highly sensitive real-time quantitative PCR. Consistent with functional loss of viral
-Gal activity, there was an average of 90 and 94% reduction of the viral
genome in tg and non-tg mice, respectively, by 28 days postinfection (Fig. 2B). At about 30 viral particles per cell in both groups of
animals, these viral loads may draw near the threshold of the lacZ assay (Fig. 2A) and thus prohibit further
identification of infected cells beyond that point. Together, these
results demonstrated no impairment in the ability of the HCV tg mice to
respond to and successfully eliminate an intrahepatic infection with an
unrelated virus.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 1.
Histochemical and immunohistochemical staining of
liver samples from HCV tg (Tg+) and non-tg (Tg ) mice. (A)
Livers from a non-tg mouse (C57BL/6J) and an HCV tg mouse stained for
HCV E2 antigen. Liver sections were stained as described in Materials
and Methods. The tg mouse demonstrated cytoplasmic distribution of
specific E2 antigen (40× objective). Parallel staining using rabbit
antibody specific for an irrelevant antigen (a salivary protein of the
sand fly Lutzomyia longipalpis) revealed no positively
stained cells in either tg or non-tg mice (data not shown). (B) -Gal
expression in hepatocytes at 3, 14, and 28 days following infection
with Ad gal. Mice were injected with 3 × 109 PFU of
Ad gal suspended in 100 µl of PBS via the tail vein. Liver sections
were stained with X-Gal and counterstained with neutral red, staining
infected hepatocytes blue and uninfected hepatocytes red. (C) T-cell
recruitment to inflammatory lesions in the livers of Ad gal-infected
mice at 3 days postinfection. Sections were incubated at 4°C
overnight with a biotinylated MAb specific for mouse CD4 or CD8
(1:500), followed by avidin-conjugated peroxidase. Representative
photomicrographs are shown.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Clearance of intrahepatic Ad gal infection in mice.
(A) Liver sections were stained with X-Gal as described in the legend
to Fig. 2A. Image analysis was used to assess the extent of Ad gal
infection. The data points represent the average ratio of infected to
uninfected hepatocytes from individual mice. While the percentage of
infected cells continued to decrease (P < 0.01),
the pattern of decline in both groups of mice remained the same
(P > 0.05). No significant difference was found
between tg (Tg+) and non-tg (Tg ) mice (P > 0.05). (B) Ad gal genome abundance in livers of infected mice as
determined by real-time quantitative PCR analysis (see Materials and
Methods). No difference in viral load, either overall
(P > 0.05) or at any given date
(P > 0.05), was found between the two groups of
mice. The viral load decreased significantly during the course of
infection in both groups of mice (P < 0.01). In
both panels, the data points were derived from two independent
experiments.
|
|
Since both humoral and cellular immune responses have been demonstrated
to play critical roles in adenovirus clearance and recovery from
experimental adenovirus infections (10, 27, 29), we
examined whether these responses to the viral infection were
quantitatively affected in tg mice. Despite the expression of the HCV
structural proteins in tg animals, tg and non-tg mice produced similar
quantities of adenovirus-specific IgG, as well as IgG2a, which is
generally accepted as an indicator of the Th1-mediated immune response
(Fig. 3A and B).
Immunohistological examinations showed that the two groups of mice had
comparable abilities to recruit CD4 and CD8 T cells to inflammatory
lesions in the liver (Fig. 1C). Also, the serum levels of TNF-
and
IL-2 in tg mice were equivalent to those found in non-tg littermates (Fig. 3C and D), suggesting no apparent
compromise in either the humoral or cellular effector mechanisms.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
Production of virus-specific IgG and cytokines following
an intrahepatic viral infection. Mice were injected with Ad gal as
for Fig. 2A, and their serum samples were collected at the indicated
time points. The error bars represent the standard deviations among
individual animals. The relative concentrations of virus-specific IgG
(A) and IgG2a (B) are expressed as absorbance, or optical density
(O.D.). The figures are representative of two or three experiments with
similar results. The levels of circulating TNF- (C) and IL-2 (D)
were determined by ELISA. Tg+, tg mice; Tg , non-tg mice.
|
|
In immunocompetent mice, adenovirus infection of the liver is
accompanied by a transient elevation of serum ALT activity, which is
followed by a significant reduction in virus within 3 weeks
(27). Thus, we determined whether the presence of the HCV
structural proteins was associated with exacerbated liver injury and/or
delayed resolution of the biochemical lesion. The peak of the chemical
liver injury occurred at 14 days postinfection in both tg and non-tg
mice, and ALT levels declined significantly in both groups of animals
thereafter (Fig. 4A). The resolution of
hepatic inflammation in both groups of mice was also confirmed by
measurements of the total liver weight, as well as resolution of acute
histopathological abnormalities (data not shown). Since the tg mice
demonstrated robust TNF-
production in response to Ad
gal
infection (Fig. 3C), we also examined the possibility that expression
of the HCV core protein in the liver could result in an exacerbated
TNF-induced apoptosis in the tg mice (4, 8, 17, 28). Using
TUNEL assays, we found that both tg and non-tg mice had elevated
numbers of apoptotic cells in the liver during the early stages of
infection. However, the number of apoptotic cells declined in both
groups as the infection progressed to the later stages (Fig. 4B). There
were no significant differences between tg and non-tg animals in these
studies.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 4.
Recovery from liver injury following Ad gal
infection in HCV tg (Tg+) and non-tg (Tg ) mice. The experiments were
carried out as described in the legend to Fig. 2A. (A) Serum ALT levels
are shown in individual animals as a function of time following
infection. There was no significant difference in ALT values between tg
and non-tg mice (P > 0.05). (B) TUNEL assay for
detection of apoptosis in the liver. Shown are the numbers of apoptotic
cells present in 10 randomly selected fields (magnification, ×40) in
individual sections. No difference in the number of apoptotic cells,
either overall (P > 0.05) or at any given time
point (P > 0.05), was found between two groups of
mice. The number of apoptotic cells decreased significantly during the
course of infection in both groups of mice (P < 0.01). The slides were scored blindly for apoptotic cells with respect
to the date and tg status of the animal.
|
|
To determine whether the absence of immunosuppression due to HCV
structural proteins that we observed in the HCV tg mice could be
restricted to the H-2b/k genetic
background or the level of tg expression, we infected BALB/c
(H-2d) mice with 3 × 108 PFU of Ad
gal and a recombinant adenovirus
(AdCE1) expressing the core and E1 segments of the HCV genome
(2). Such infection resulted in a substantially higher
abundance of the intracellular HCV core protein (Fig.
5A). Despite this, we observed a
significant reduction of viral load in the BALB/c mice infected with
AdCE1, which was comparable to that in the mice infected with Ad
gal (Fig. 5B). Both groups of mice recovered from the infection, as reflected in a decrease in serum ALT activities from early peak values
(data not shown). These results lend strong support to the conclusion
that in mice the HCV core protein does not hinder the host's ability
to resolve an intrahepatic viral infection. This absence of
immunosuppression is neither mouse strain specific nor dependent on the
level of HCV core expression.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 5.
Clearance of intrahepatic Ad gal and AdCE1 infections
in BALB/c mice. (A) Immunoblot detection of the HCV core protein in the
liver of an AdCE1-infected mouse. Huh7/191-20 is a stably transfected
cell line that expresses the HCV core, E1, and E2 proteins (see
Materials and Methods). Probing was carried out with a mixture of MAbs
specific for HCV core, -actin, and adenovirus hexon protein,
followed by a horseradish peroxidase-conjugated anti-mouse IgG. (B)
Ad gal and AdCE1 copy numbers in the liver DNA extracts were assessed
by real-time quantitative PCR analysis, as described in the legend to
Fig. 2B. All data points represent an average of two or three animals
in each group, and the error bars depict standard deviations.
|
|
 |
DISCUSSION |
Using a series of vaccinia virus/HCV recombinants, Large et al.
have examined the influence of specific HCV gene products on the immune
responses to vaccinia virus in a murine model (14). In
that study, vaccinia virus recombinants expressing various regions of
the HCV polyprotein were inoculated intraperitoneally into
naïve BALB/c mice. The HCV core protein contributed to a greater pathogenicity of vaccinia virus/HCV recombinants in BALB/c mice
(H-2d), suggesting that it might
contribute to viral persistence by directly suppressing host immune
responses, in particular, the generation of virus-specific CTL. In the
present study, however, we evaluated the effect of the HCV core protein
in tg mice that express an abundance of the HCV structural proteins
that is much closer to that found in infected human livers.
Surprisingly, we found no evidence of suppression of intrahepatic viral
clearance mechanisms in these mice
(H-2b/k) by the HCV core, E1, or E2
protein. Mice from a genetically different background
(H-2d) also efficiently cleared a
recombinant adenovirus that expressed a much higher level of the HCV
core protein. Mice from both genetic backgrounds made timely recoveries
from the intrahepatic infection. The absence of demonstrable
immunosuppression cannot be attributed to the lack of a need for
effective immune responses to clear a recombinant adenovirus, since
persistence of the virus has been demonstrated in nude mice by Southern
blot analysis and
-Gal histochemistry for up to 60 days
postinfection (26, 29). In addition, administration of
immunosuppressants, such as FK506, cyclosporine A, dexamethasone, or
Ab-soluble fusion protein blocking CD40 ligand, has been shown to
significantly prolong the presence of the virus in infected mouse liver
(12, 23, 29). In patients with hepatitis C, HCV RNA is
typically detectable only by RT-PCR, and demonstration of viral
proteins in the liver is often difficult. Thus, the demonstration of
HCV mRNA transcripts in the tg mice coupled with evidence of
polyprotein expression and steatosis (14a) indicates that
the abundance of HCV proteins expressed in tg mice was adequate for the
intended purpose of this study.
The difference between our results and those of Large et al.
(14) may be in the type of challenge infection. Vaccinia
virus can replicate in the ovaries and spleen in addition to the liver in mice. The greater pathogenicity of the core-expressing vaccinia virus was found by Large et al. to be associated with progressive lytic
infection and necrosis in those organs (14). In contrast, the mice used in our study were challenged with a recombinant adenovirus that is highly hepatotropic when inoculated through the tail
vein. Such an experimental system is more likely to reflect the
situation existing in the HCV-infected livers of patients.
Apoptosis has been suggested as a common pathway to virus clearance by
host CTL and NK cells. Many virus genomes encode proteins that suppress
apoptosis in order to escape immune attack by the host
(18). Conflicting results have suggested that the HCV core protein can either protect transfected cells from Fas- and
TNF-
-induced apoptotic cell death or sensitize them to it (8,
16, 28). Our results suggest that HCV core neither exacerbates
nor inhibits apoptosis in vivo in the face of a robust, endogenous
TNF-
response. Furthermore, as our tg-mouse experiments have shown,
the HCV E2 protein does not hamper the host's ability to mount
effective intrahepatic immune responses, even though it has been
suggested to interfere with and suppress PKR responses
(21).
These data clarify previous contradictory reports regarding the
functions of core and E2 proteins, as they are derived from an in vivo
system in which the abundances of these proteins are more reflective of
the situation in human patients. While our data favor a model in which
HCV circumvents the immune responses through a mechanism that does not
involve general immunosuppression, they do not exclude the possibility
that the virus modulates the complex interplay between the dynamics of
viral diversity and the early breadth of CTL responses. For instance,
viral escape mutants have been shown to give rise to T-cell receptor
antagonists capable of inhibiting CTL clones that recognize prototypic
viral epitopes (3, 11, 22). In addition, the additive or
synergistic effects of other HCV proteins not expressed in these
studies (e.g., NS5A) may conceivably contribute to viral resistance to
the IFN-mediated antiviral mechanism, leading to persistent infection
(7).
 |
ACKNOWLEDGMENTS |
We gratefully acknowledge Tony Carroll at Glaxo Wellcome for
providing AdCE1 virus, Kui Li for providing Huh7/191-20 cells, Elbert
Whorton for statistical analysis, Shu-Yuan Xiao for evaluating histopathological sections, Hong Diao for excellent technical assistance, Chiaho Shih for critical reading of the manuscript, and
Mardelle Susman for assistance with manuscript preparation.
This work was supported by grants from the National Cancer Institute
(SBIR-CA88770), the National Institute of Allergy and Infectious
Diseases (U19-AI40035), and the John Sealy Memorial Endowment Fund for
Biomedical Research.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1019. Phone: (409) 747-0186. Fax:
(409) 747-6869. E-mail: jisun{at}utmb.edu.
 |
REFERENCES |
| 1.
|
Alter, M. J.,
D. Kruszon-Moran,
O. V. Nainan,
G. M. McQuillan,
F. Gao,
L. A. Moyer,
R. A. Kaslow, and H. S. Margolis.
1999.
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.
N. Engl. J. Med.
341:556-562[Abstract/Free Full Text].
|
| 2.
|
Bruna-Romero, O.,
J. J. Lasarte,
G. Wilkinson,
K. Grace,
B. Clarke,
F. Borras-Cuesta, and J. Prieto.
1997.
Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus.
Hepatology
25:470-477[CrossRef][Medline].
|
| 3.
|
Chang, K. M.,
B. Rehermann,
J. G. McHutchison,
C. Pasquinelli,
S. Southwood,
A. Sette, and F. V. Chisari.
1997.
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus.
J. Clin. Investig.
100:2376-2385[Medline].
|
| 4.
|
Chen, C. M.,
L. R. You,
L. H. Hwang, and Y. H. Lee.
1997.
Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin- receptor modulates the signal pathway of the lymphotoxin- receptor.
J. Virol.
71:9417-9426[Abstract].
|
| 5.
|
Chirmule, N.,
A. Truneh,
S. E. Haecker,
J. Tazelaar,
G. Gao,
S. E. Raper,
J. V. Hughes, and J. M. Wilson.
1999.
Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody.
J. Immunol.
163:448-455[Abstract/Free Full Text].
|
| 6.
|
Gale, M., Jr.,
B. Kwieciszewski,
M. Dossett,
H. Nakao, and M. G. Katze.
1999.
Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase.
J. Virol.
73:6506-6516[Abstract/Free Full Text].
|
| 7.
|
Gale, M. J., Jr.,
M. J. Korth,
N. M. Tang,
S. L. Tan,
D. A. Hopkins,
T. E. Dever,
S. J. Polyak,
D. R. Gretch, and M. G. Katze.
1997.
Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.
Virology
230:217-227[CrossRef][Medline].
|
| 8.
|
Hahn, C. S.,
Y. G. Cho,
B. S. Kang,
I. M. Lester, and Y. S. Hahn.
2000.
The HCV core protein acts as a positive regulator of Fas-mediated apoptosis in a human lymphoblastoid T cell line.
Virology
276:127-137[CrossRef][Medline].
|
| 9.
|
Herz, J., and R. D. Gerard.
1993.
Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice.
Proc. Natl. Acad. Sci. USA
90:2812-2816[Abstract/Free Full Text].
|
| 10.
|
Jooss, K.,
H. C. Ertl, and J. M. Wilson.
1998.
Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver.
J. Virol.
72:2945-2954[Abstract/Free Full Text].
|
| 11.
|
Kaneko, T.,
T. Moriyama,
K. Udaka,
K. Hiroishi,
H. Kita,
H. Okamoto,
H. Yagita,
K. Okumura, and M. Imawari.
1997.
Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope.
Eur. J. Immunol.
27:1782-1787[Medline].
|
| 12.
|
Kay, M. A.,
L. Meuse,
A. M. Gown,
P. Linsley,
D. Hollenbaugh,
A. Aruffo,
H. D. Ochs, and C. B. Wilson.
1997.
Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver.
Proc. Natl. Acad. Sci. USA
94:4686-4691[Abstract/Free Full Text].
|
| 13.
|
Kittlesen, D. J.,
K. A. Chianese-Bullock,
Z. Q. Yao,
T. J. Braciale, and Y. S. Hahn.
2000.
Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation.
J. Clin. Investig.
106:1239-1249[Medline].
|
| 14.
|
Large, M. K.,
D. J. Kittlesen, and Y. S. Hahn.
1999.
Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence.
J. Immunol.
162:931-938[Abstract/Free Full Text].
|
| 14a.
| Lerat, H., M. Honda, M. Beard, K. Loesch, J. Sun, Y. Yang, M. Okuda, R. Gosert, S. Y. Xiao, S. A. Weinman, and S. M.
Lemon. Steatosis and liver cancer in transgenic mice expressing
the structural and nonstructural proteins of hepatitis C virus.
Gastroenterology, in press.
|
| 15.
|
Major, M. E.,
K. Mihalik,
J. Fernandez,
J. Seidman,
D. Kleiner,
A. A. Kolykhalov,
C. M. Rice, and S. M. Feinstone.
1999.
Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus.
J. Virol.
73:3317-3325[Abstract/Free Full Text].
|
| 16.
|
Marusawa, H.,
M. Hijikata,
T. Chiba, and K. Shimotohno.
1999.
Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF- B activation.
J. Virol.
73:4713-4720[Abstract/Free Full Text].
|
| 17.
|
Matsumoto, M.,
T. Y. Hsieh,
N. Zhu,
T. VanArsdale,
S. B. Hwang,
K. S. Jeng,
A. E. Gorbalenya,
S. Y. Lo,
J. H. Ou,
C. F. Ware, and M. M. Lai.
1997.
Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin- receptor.
J. Virol.
71:1301-1309[Abstract].
|
| 18.
|
Moretta, A.
1997.
Molecular mechanisms in cell-mediated cytotoxicity.
Cell
90:13-18[CrossRef][Medline].
|
| 19.
|
O'Farrelly, C., and I. N. Crispe.
1999.
Prometheus through the looking glass: reflections on the hepatic immune system.
Immunol. Today
20:394-398[CrossRef][Medline].
|
| 20.
|
Sun, J., and R. L. Tarleton.
1993.
Predominance of CD8+ T lymphocytes in the inflammatory lesions of mice with acute Trypanosoma cruzi infection.
Am. J. Trop. Med. Hyg.
48:161-169.
|
| 21.
|
Taylor, D. R.,
S. T. Shi,
P. R. Romano,
G. N. Barber, and M. M. Lai.
1999.
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.
Science
285:107-110[Abstract/Free Full Text].
|
| 22.
|
Tsai, S. L.,
Y. M. Chen,
M. H. Chen,
C. Y. Huang,
I. S. Sheen,
C. T. Yeh,
J. H. Huang,
G. C. Kuo, and Y. F. Liaw.
1998.
Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity.
Gastroenterology
115:954-965[CrossRef][Medline].
|
| 23.
|
Vilquin, J. T.,
B. Guerette,
I. Kinoshita,
B. Roy,
M. Goulet,
C. Gravel,
R. Roy, and J. P. Tremblay.
1995.
FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer.
Hum. Gene Ther.
6:1391-1401[Medline].
|
| 24.
|
von Boehmer, H.
1997.
Lymphotoxins: from cytotoxicity to lymphoid organogenesis.
Proc. Natl. Acad. Sci. USA
94:8926-8927[Free Full Text].
|
| 25.
|
Weiner, A.,
A. L. Erickson,
J. Kansopon,
K. Crawford,
E. Muchmore,
A. L. Hughes,
M. Houghton, and C. M. Walker.
1995.
Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.
Proc. Natl. Acad. Sci. USA
92:2755-2759[Abstract/Free Full Text].
|
| 26.
|
Yang, Y.,
F. A. Nunes,
K. Berencsi,
E. Gonczol,
J. F. Engelhardt, and J. M. Wilson.
1994.
Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.
Nat. Genet.
7:362-369[CrossRef][Medline].
|
| 27.
|
Yang, Y.,
F. A. Nunes,
K. Berencsi,
E. E. Furth,
E. Gonczol, and J. M. Wilson.
1994.
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
Proc. Natl. Acad. Sci. USA
91:4407-4411[Abstract/Free Full Text].
|
| 28.
|
Zhu, N.,
A. Khoshnan,
R. Schneider,
M. Matsumoto,
G. Dennert,
C. Ware, and M. M. Lai.
1998.
Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.
J. Virol.
72:3691-3697[Abstract/Free Full Text].
|
| 29.
|
Zsengeller, Z. K.,
S. E. Wert,
W. M. Hull,
X. Hu,
S. Yei,
B. C. Trapnell, and J. A. Whitsett.
1995.
Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice.
Hum. Gene Ther.
6:457-467[Medline].
|
Journal of Virology, December 2001, p. 11992-11998, Vol. 75, No. 24
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.24.11992-11998.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kanda, T., Steele, R., Ray, R., Ray, R. B.
(2009). Inhibition of Intrahepatic Gamma Interferon Production by Hepatitis C Virus Nonstructural Protein 5A in Transgenic Mice. J. Virol.
83: 8463-8469
[Abstract]
[Full Text]
-
Sun, J., Tumurbaatar, B., Jia, J., Diao, H., Bodola, F., Lemon, S. M., Tang, W., Bowen, D. G., McCaughan, G. W., Bertolino, P., Chan, T.-S.
(2005). Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury. J. Virol.
79: 10730-10739
[Abstract]
[Full Text]
-
Matsui, M., Moriya, O., Belladonna, M. L., Kamiya, S., Lemonnier, F. A., Yoshimoto, T., Akatsuka, T.
(2004). Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice. J. Virol.
78: 9093-9104
[Abstract]
[Full Text]
-
Sarobe, P., Lasarte, J. J., Zabaleta, A., Arribillaga, L., Arina, A., Melero, I., Borras-Cuesta, F., Prieto, J.
(2003). Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses. J. Virol.
77: 10862-10871
[Abstract]
[Full Text]
-
Soguero, C., Joo, M., Chianese-Bullock, K. A., Nguyen, D. T., Tung, K., Hahn, Y. S.
(2002). Hepatitis C Virus Core Protein Leads to Immune Suppression and Liver Damage in a Transgenic Murine Model. J. Virol.
76: 9345-9354
[Abstract]
[Full Text]